IL-6-mediated endothelial injury impairs antiviral humoral immunity after bone marrow transplantation

J Clin Invest. 2024 Apr 1;134(7):e174184. doi: 10.1172/JCI174184.

Abstract

Endothelial function and integrity are compromised after allogeneic bone marrow transplantation (BMT), but how this affects immune responses broadly remains unknown. Using a preclinical model of CMV reactivation after BMT, we found compromised antiviral humoral responses induced by IL-6 signaling. IL-6 signaling in T cells maintained Th1 cells, resulting in sustained IFN-γ secretion, which promoted endothelial cell (EC) injury, loss of the neonatal Fc receptor (FcRn) responsible for IgG recycling, and rapid IgG loss. T cell-specific deletion of IL-6R led to persistence of recipient-derived, CMV-specific IgG and inhibited CMV reactivation. Deletion of IFN-γ in donor T cells also eliminated EC injury and FcRn loss. In a phase III clinical trial, blockade of IL-6R with tocilizumab promoted CMV-specific IgG persistence and significantly attenuated early HCMV reactivation. In sum, IL-6 invoked IFN-γ-dependent EC injury and consequent IgG loss, leading to CMV reactivation. Hence, cytokine inhibition represents a logical strategy to prevent endothelial injury, thereby preserving humoral immunity after immunotherapy.

Keywords: Bone marrow transplantation; Cytokines; Immunoglobulins; Transplantation.

MeSH terms

  • Animals
  • Antiviral Agents
  • Bone Marrow Transplantation* / adverse effects
  • Cytomegalovirus Infections* / immunology
  • Cytomegalovirus Infections* / metabolism
  • Immunity, Humoral*
  • Immunoglobulin G
  • Interleukin-6* / metabolism
  • Mice

Substances

  • Antiviral Agents
  • Immunoglobulin G
  • Interleukin-6